Clinical Trial

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is a phase 1B/2 open-label, study to determine safety and preliminary efficacy of Q702 in combination with pembrolizumab in study subjects with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-06-27; most recent amendment 2026-02-23.
Status change: Recruiting → Active, Not Recruiting 2026-02-23
Status change: Not Yet Recruiting → Recruiting 2023-01-31
Trial Details
NCT Number NCT05438420
Lead Sponsor Qurient Co., Ltd.
Collaborators: Merck Sharp & Dohme LLC
Conditions Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer
Enrollment 120 participants
Start Date 2023-01-12
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-24